GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
Ann Rheum Dis
.
2018 May;77(5):e23.
doi: 10.1136/annrheumdis-2017-212004.
Epub 2017 Jul 26.
Authors
William Tillett
1
2
,
Ana-Maria Orbai
3
,
Alexis Ogdie
4
,
Ying Ying Leung
5
,
Vibeke Strand
6
,
Dafna D Gladman
7
,
Philip J Mease
8
,
Laura C Coates
9
;
GRAPPA OMERACT Psoriatic Arthritis working group
Affiliations
1
Royal National Hospital for Rheumatic Disease, Bath, UK.
2
Pharmacy and Pharmacology, University of Bath, Bath, UK.
3
Department of Medicine/Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
4
Division of Rheumatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
5
Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore.
6
Department of Immunology/Rheumatology, Stanford University, Stanford, California, USA.
7
Krembil Research Institute, University Health Network,Toronto Western Hospital, Toronto, Ontario, Canada.
8
Department of Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA.
9
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
PMID:
28747326
DOI:
10.1136/annrheumdis-2017-212004
No abstract available
Keywords:
disease activity; psoriatic arthritis; treatment.
Publication types
Letter
Comment
MeSH terms
Arthritis, Psoriatic*
Enthesopathy*
Humans
Longitudinal Studies
Psoriasis